partnerspartners
The Spiegelmer discovery platform is broadly applicable across many therapeutic areas. As a consequence, partnering is an important part of NOXXON's business strategy to advance individual Spiegelmers and the substance class as a whole. NOXXON has attracted the attention of many major drug developers. We are proud to collaborate with some of the top pharmaceutical companies to expedite the progression of Spiegelmer therapeutics into the clinic and to patients.
In June 2008 NOXXON entered into a licensing and drug discovery agreement with the US pharma company Eli Lilly and Company to develop Spiegelmer-based products for the treatment of migraine.
In November of 2007 NOXXON entered into a Research & Development Agreement with F. Hoffmann-La Roche regarding the discovery and development of Spiegelmers for the treatment of inflammatory diseases.
Beside the corporate partnerships, NOXXON collaborates with many academic investigators worldwide. The list below names some of NOXXON's scientific advisors and provides a sample of currently exisiting academic cooperations:
PD Dr. Hans-Joachim Anders
Universität München, Medizinische Poliklinik
München, Germany
Prof. Dr. Dr. Christian Betzel
Universität Hamburg, Fachbereich Chemie
c/o DESY, Geb. 22a
Hamburg, Germany
Prof. Dr. Richard Horuk
University of California Davis
Sacramento, CA, USA and
Touro University
Vallejo, CA, USA
Peter Rossing, MD, DMSc
Steno Diabetes Center
Gentofte, Denmark
Prof. Dr. Christoph Wanner
Universitätsklinik Würzburg
Würzburg, Germany
Prof. Dr. Anthony D. Ho
Department of Internal Medicine V (Hematology, Oncology and Rheumatology)
University Clinic Heidelberg, Germany
Prof. Dr. Nikolaus Kröger
Department of Bone Marrow Transplantation
University Hospital Hamburg-Eppendorf, Germany
PD Dr. Armin Gerbitz
Medical Department, Division of Hematology, Oncology
Charité University Medicine Berlin, Germany
PD Dr. Kai Hübel
Internal Medicine I (Hematology and Oncology)
University Hospital of Cologne, Cologne Germany